Top Markets
Coin of the day
IMBdx IMBdx

IMBdx

461030
Rank in Stocks #27739
IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for... IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for cancer detection and management. The company's core mission revolves around three key areas: facilitating the diagnosis and treatment strategies for advanced-stage cancers, enabling the early identification of cancer recurrence after surgical interventions, and providing solutions for the early diagnosis of cancer. Its notable product offerings include AlphaLiquid, CancerDetect, and CancerFind. The firm was established by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018, and maintains its headquarters in Seoul, South Korea.
Share Price
$2.14
Market Cap
$30.63M
Change (1 day)
0.16%
Change (1 year)
-62.09%
Country
KR
Trade IMBdx (461030)

Category

P/B ratio for IMBdx (461030)
P/B ratio as of 2026 TTM: 0
According to IMBdx latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for IMBdx from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH